Commentary on gait analysis in Duchenne muscular dystrophy: integrating contracture, strength, and kinematic perspectives

Abstract

Walking ability in Duchenne muscular dystrophy (DMD) deteriorates progressively until complete loss of function. Interventions aimed at maintaining ambulatory ability rely on accurate clinical-based scores and evaluations of walking. The commentary concerns a study that provides a comprehensive look at how contractures, muscle weakness, and gait deviations intertwine to shape mobility in boys with DMD. The described eight-year longitudinal work offers a significant contribution to the understanding of longitudinal gait changes in DMD and the clinical value of such longitudinal data. The findings confirm that gait spatiotemporal parameters, particularly speed, stride length, and cadence, serve as sensitive markers of disease progression, closely linked to specific biomechanical impairments. The study strongly suggests that the integration of quantitative gait metrics into both clinical and research frameworks will be essential for optimizing patient monitoring and evaluating emerging therapeutics.

Keywords

Duchenne muscular dystrophy / gait analysis / contractures / muscle weakness / spatiotemporal parameters / pelvic kinematics

References

[1] Bushby K,Finkel R,Birnkrant DJ.et al. ; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care Lancet Neurol. 2010 9 177 89

[2] Radley-Crabb HG,Marini JC,Sosa HA,Castillo LI,Grounds MD,Fiorotto ML. Dystropathology increases energy expenditure and protein turnover in the mdx mouse model of Duchenne muscular dystrophy PLoS ONE. 2014 9 e89277 PMC3929705

[3] Bagley A,Sienko S,Buckon CE.et al. What influences changes in gait spatiotemporal parameters in boys with Duchenne muscular dystrophy? Focusing on contractures, muscle strength, and gait deviations Rare Dis Orphan Drugs J. 2025 4 19

[4] Choi YA,Chun SM,Kim Y,Shin HI. Lower extremity joint contracture according to ambulatory status in children with Duchenne muscular dystrophy BMC Musculoskelet Disord. 2018 19 287 PMC6094451

[5] Willcocks RJ,Barnard AM,Wortman RJ.et al. Development of contractures in DMD in relation to MRI-determined muscle quality and ambulatory function J Neuromuscul Dis. 2022 9 289 302 9257436

[6] Skalsky AJ,McDonald CM. Prevention and management of limb contractures in neuromuscular diseases Phys Med Rehabil Clin N Am. 2012 23 675 87 PMC3482407

[7] Perry J. Gait analysis: normal and pathological function. Boca Raton: CRC Press; 1992

[8] Hsu JD,Furumasu J. Gait and posture changes in the Duchenne muscular dystrophy child Clin Orthop. 1993 122 5

[9] Heberer K,Fowler E,Staudt L.et al. Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy Gait Posture. 2016 48 159 64

[10] Hoffman L. Longitudinal analysis: modeling within-person fluctuation and change. New York: Routledge; 2014

[11] Lim KRQ,Nguyen Q,Yokota T. Genotype-phenotype correlations in Duchenne and Becker muscular dystrophy patients from the Canadian neuromuscular disease registry J Pers Med. 2020 10 241 PMC7712074

[12] Goudriaan M,Van den Hauwe M,Dekeerle J.et al. Gait deviations in Duchenne muscular dystrophy-Part 1. A systematic review Gait Posture. 2018 62 247 61

[13] Gaudreault N,Gravel D,Nadeau S,Houde S,Gagnon D. Gait patterns comparison of children with Duchenne muscular dystrophy to those of control subjects considering the effect of gait velocity Gait Posture. 2010 32 342 7

[14] Sienko S,Buckon C,Bagley A.et al. Kinematic changes in gait in boys with Duchenne muscular dystrophy: utility of the gait deviation index, the gait profile score and the gait variable scores Gait Posture. 2023 100 157 64

[15] Buckon CE,Sienko SE,Fowler EG.et al. A longitudinal study of quantitative muscle strength and functional motor ability in ambulatory boys with Duchenne muscular dystrophy J Neuromuscul Dis. 2022;9:321-34

[16] Markati T,Oskoui M,Farrar MA,Duong T,Goemans N,Servais L. Emerging therapies for Duchenne muscular dystrophy Lancet Neurol. 2022 21 814 29

[17] Sankar WN,Laird CT,Baldwin KD. Hip range of motion in children: what is the norm? J Pediatr Orthop. 2012;32:399-405

[18] McDonald CM,Henricson EK,Abresch RT.et al. ; CINRG Investigators. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study Lancet. 2018 391 451 61

[19] Haque US,Yokota T. Gene editing for Duchenne muscular dystrophy: from experimental models to emerging therapies Degener Neurol Neuromuscul Dis. 2025 15 17 40 12002074

[20] D’Angelo MG,Berti M,Piccinini L.et al. Gait pattern in Duchenne muscular dystrophy Gait Posture. 2009 29 36 41

[21] Sienko S,Buckon CE,Bagley A.et al. Longitudinal changes in energy cost during walking in boys with Duchenne muscular dystrophy (DMD) Gait Posture. 2021 90 301 6